chrisvoncsefalvay/vaers-outcomes huggingface dataset:
About 30 days after receiving my last vaccine, I started to experience neck pain. I attributed it to possibly doing something wrong, because I'm a very active person. I began to have head and jaw pain as well. I went to the dentist, and he didn't see any problems. He told me to see a neurologist. That neurologist performed temporal biopsies and diagnosed me with temporal arteritis. This doctor told me that I needed to see a Rheumatologist. All three physicians put me on an 80mg dosage of prednisone. The day I started taking the pills, I was experiencing color flashes in my eyes, so the prednisone helped me. I had an appointment with my internist, and he noticed swelling in my ankle. He did a doppler test and noticed there was a blood clot from my calf to just above my knee. I was given ELIQUIS to take twice a day. I have my blood checked every two weeks. I have been taken off of the prednisone after lowering the dosage over time.
34 y.o. male with no significant medical history came to medical center for evaluation of leukocytosis  (WBC-290,000) found on a routine annual health check up with his PCP. In the past few weeks, he has had occasional night sweats and left sided shoulder pain on deep inspiration. No fever or loss of appetite or weight.
had to stay in bed for 2 days feeling not so good, but it wasn't so extreme (compared to the third shot).; fluy; felt achy; This spontaneous case was reported by a consumer and describes the occurrence of FEELING ABNORMAL (had to stay in bed for 2 days feeling not so good, but it wasn't so extreme (compared to the third shot).), INFLUENZA LIKE ILLNESS (fluy) and MYALGIA (felt achy) in a 44-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 008E21A, 046A21A and 011F21A) for COVID-19 vaccination.     Concomitant products included VITAMINS NOS for an unknown indication.   On 22-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 23-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 06-Oct-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced FEELING ABNORMAL (had to stay in bed for 2 days feeling not so good, but it wasn't so extreme (compared to the third shot).), INFLUENZA LIKE ILLNESS (fluy) and MYALGIA (felt achy). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE, PARACETAMOL (TYLENOL PM) for Adverse event, at an unspecified dose and frequency. At the time of the report, FEELING ABNORMAL (had to stay in bed for 2 days feeling not so good, but it wasn't so extreme (compared to the third shot).), INFLUENZA LIKE ILLNESS (fluy) and MYALGIA (felt achy) outcome was unknown.            This case was linked to MOD-2021-345908 (Patient Link).
No additional AE information provided; HCP states that ROTATEQ was administered to a patient after temperature excursions; This spontaneous report was received from a pharmacist referring to a patient of unknown age and gender. The patient's medical history, historical drugs, concurrent conditions and concomitant medications were not provided.      On 30-SEP-2022, the patient was vaccinated with an improperly stored dose of rotavirus vaccine, live, oral, pentavalent(ROTATEQ) lot number W002561, expiration date 07-OCT-2023 (dose and route of administration not reported) for prophylaxis (product storage error). No adverse event was reported.  The temperature excursion was of 9.13 degrees Celsius (°C) for 1 hour and of -8.4°C for 37 hours and 15 minutes. No previous excursions were detected.
Information has been received from a physician concerning a 61 year old male with asthma, eczema, benign prostatic hyperplasia and pollen allergy who on 28-DEC-2007 was vaccinated subcutaneously into the left upper arm with "a single dose" of Zostavax (Oka/Merck) and influenza virus vaccine (unspecified), which was administered in the right upper arm.  Concomitant therapy included saw palmetto.  On 01-JAN-2008, four days after being administered the vaccines; the patient developed a macular-papular rash on his back.  The rash was reported to have started on the right mid-thorax and spread to the left mid-thorax with a localized area under the left breast.  The patient complained of a "sunburn-like burning" in the area of the rash.  The patient self treated the rash "DESONIDE" Cream and the rash resolved.  The rash returned after the "DESONIDE" Cream was discontinued.  The patient was examined in the office on 29 JAN 2008 at which time the exam revealed a 6 cm rash.  The burning sensation was improved at that time.  The physician recommended that patient continue to apply the "DESONIDE" Cream as needed.  At the time of reporting the patient had not yet recovered.  There was no product quality complaint.  There were no lab diagnostic studies performed.  Additional information has been requested. In follow up the physician indicated that the patient received both ZOSTAVAX (Merck) (lot# 14144) and FLULAVAL (lot# AFLLAAUWAAVN708) the same day. Four days after the patient received the injections he developed irritation, sunburn and chill-like feeling, no fever. The patient used hydrocortisone 1% cream with relief. The patient was seen on 29-JAN-2008 and had a maculopapular rash below his shoulder blades he recovered on 29-Feb-2008. Additional information has been requested.
she has also had abnormal pap smears with HPV in the past (dates unspecified); she has also had abnormal pap smears with HPV in the past (dates unspecified); Bleeding vaginal; This spontaneous report Was received from a pharmacist referring to herself, a female non-pregnant patient of unknown age. No patient's pertinent medical history, concurrent conditions, drug reactions or allergies, nor concomitant therapies were reported.     On an unspecified date in July 2021 (also reported as "beginning of July"), the patient was vaccinated with her second dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast)(GARDASIL 9) 0.5 milliliter, by intramuscular route, (strength, frequency, anatomical location, lot number an expiration date were not reported), as human papillomavirus (HPV) prevention.  On an unspecified date in 2021, (also reported as "about two weeks after the secondo dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast)(GARDASIL 9)), the patient began to experience vaginal bleeding (vaginal haemorrhage). Additionally, on an unknown date (also reported "in the past"), the patient had abnormal Papanicolaou smear with human papillomavirus (HPV) (papilloma viral infection and smear cervix abnormal). It was reported that on an unknown date, the patient sought medical attention, was treated with change the "birth control dosage" and would get unspecified bloodwork in a couple of days. At the time of reporting, the outcome of events was reported as not recovered. The reporter did not assess the causal relationship between the events and hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast)(GARDASIL 9).
DTaP given 11/22/02. 11/23/02 mom noticed redness and swelling, hot and painful; size increased over weekend. Came to health department for evaluation on Monday 11/25. Child is in NAD, A&A, afebrile, localized reaction only.
bruise noted on day 2, then bruise resolved and small, firm, mobile, subcutansous mass was noted. Mass is slowly getting smaller, but still present 1 month later 11/04/2022
Sore right arm   Took  naproxen 220mg 6 pm. No relief.  Headache , Nausea, tachycardia , sweating , faint feeling, abdominal cramping 11:00pm Vomited x 1 at 11:30pm Severe Diarrhea started at 11:30 and lasted for next 20 hours. I did not eat any food for the next 20 hours. Only took clear liquids.  1:30 am 3/13/2021 zofran 4 mg some relief of cramping. No relief of diarrhea.  Imodium otc
Temp to 100, red welt, swollen lump on thigh at innoculation shite. Growing over 48 hours following immunization. Not wanting to walk on leg initially. Now better. On Motrin/Tylenol.
pt recv vax & reporter noted it was felt that the anti-HBc was a false pos which was probably due to cross-sensitivity; No further info provided;
p/vax pt adm to hosp & underwent surgery & subsequently was dx w/ileocecal intussusception;
Severe pain in arm, followed by fever, headache, neck pain, swollen arm with bright red patches, joint pain.
This spontaneous report received from a patient via other manufacturer (Pfizer) concerned a patient of unspecified age and sex. The patient's height, and weight were not reported. The patient's concurrent conditions included: lupus, ehlers danlos syndrome, and pots (postural orthostatic tachycardia syndrome). The patient experienced drug allergy when treated with Suprax (cefotaxime sodium) for drug used for unknown indication.  The patient received covid-19 vaccine ad26.cov2.s (dose number in series 1) (suspension for injection, route of admin, and batch number were not reported, expiry: unknown) dose, start therapy date were not reported, 1 total for covid-19 prophylaxis. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers.It was unknown if patient experienced any adverse event after vaccination with first dose of covid-19 vaccine ad26.cov2.s (dose number in series 1). The patient additionally received non-company suspect vaccine included: Moderna covid-19 vaccine (elasomeran) (dose number in series 2) (form of admin, route of admin, and batch number were not reported, expiry: unknown) dose was not reported, administered on 01-NOV-2021 for covid-19 prophylaxis which was revaccination with different covid-19 vaccine (dose number in series 2). No concomitant medications were reported.  On an unspecified date, the patient experienced suspected covid-19 infection (dose number in series 2). The patient received non company suspect Paxlovid (form of admin and route were not reported, batch number unknown and expiry: unknown) dose was not reported, administered from 05-SEP-2022 to 10-SEP-2022 for covid-19 treatment.  On 15-SEP-2022 (5 days after finishing Paxlovid), the patient experienced covid-19 rebound with symptoms (dose number in series 2). The action taken with covid-19 vaccine ad26.cov2.s, and elasomeran was not applicable and with Paxlovid was treatment discontinued. The patient had not recovered from suspected covid-19 infection, and the outcome of revaccination with different covid-19 vaccine was not reported. This report was non-serious. Sender's Comments: V0- Medical assessment comment is not required as per standard procedure as case was assessed as non-serious.
Had the chills the next day, all day, and then two days later I was extremely weak. with severe diarrhea. pain between my shoulder blades
19MAY94 woke up & 2AM-4AM & 8AM c/o pain in lt arm; arm inflammed about size of quarter over site of DTP;
This is a spontaneous report received from a noncontactable reporter (other HCP). A 64-year-old female patient received the 3rd (booster) dose of BNT162B2 (Comirnaty, batch/lot# FD7218), at the age of 64, on Jan 13, 2022, single dose, for COVID-19 immunisation. The patient's medical history and concomitant medications not reported. Vaccination history included the 1st and 2nd dose of the COVID-19 vaccine (batch/lot# unknown/not available/provided), for COVID-19 immunisation. The patient developed pyrexia/fever, and nausea, onset Jan 2022, with outcome of unknown. No follow-up attempts possible. No further information expected.
ADMISSION DATE: 11/22/2021 - 48 y/o female with history of HTN who was diagnosed with Covid-19 on 11/15 who p/w sob. The patient notes symptoms started on 11/11 with a dry cough and sinus like symptoms. She states things seemed to progress, so she was tested at Urgent Care. She received monoclonal ab on 11/18. The patient is fully vaccinated with the J&J vaccine in Sept. She notes that over the past week she has had more DOE. She also has had myalgias and diarrhea. She endorses abd pain where the injections from the monoclonal ab were, but also states she has chest pain after she tries to catch her breath from any exertion. She notes some tingling in her arms/hands as well.  Imaging with ct abd/
Six days after receiving the 1st dose of the Pfizer vaccine, I experienced a sudden, total loss of hearing in the left ear. This was accompanied by extreme vertigo and loud tinnitus which has not abated.  I have visited an ENT specialist and had three audiology tests, which has confirmed that there is no hearing function in the left ear.  ENT diagnosed as  labyrinthitis due to viral infection. Tried to reduce inflammation and potentially restore hearing function by injecting steroids directly into the ear. These treatments have not worked.   I received the 2nd dose of the vaccine on 4/11/21 as scheduled.
PRESENTED TO ER WITH ALTERED MENTAL STATUS 10/30/23. CT BRAIN SHOWED LARGE CEREBELLAR HEMORRHAGE. INTUBATED FOR AIRWAY CONTROL. NEUROSURGERY CONSULTED AND DEEMED NOT A SURGICAL CANDIDATE. FAMILY OPTED FOR HOSPICE CARE
Pt experienced severe hypoglycemic event (POC=38) following his first COVID-19 vaccine dose. He was found driving the wrong way down the highway with no memory of the event once stopped by authorities. He was admitted with hypoglycemia and chest pain. His home diabetes coverage is an insulin pump and there was denial of decreased PO intake. The insulin pump was stopped once the pt was admitted. His glucose improved and insulin regular SSI was initiated. He was brought for cardiac cath 2/2  with no new issues seen. The patient stabilized, was set for follow-up with PCP and endocrinologist and discharged 2/4.
Given IPOL vaccination in left thigh on 5/26 on 5/27 went to ER with redness warmth at site low grade fever symptoms resolved in 2 days
Dose given more than 12 hour post-puncture; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Dose given more than 12 hour post-puncture) in an 18-year-old male patient who received mRNA-1273 (Spikevax) (batch nos. 033K21-2A and 068H21A) for COVID-19 vaccination.     No Medical History information was reported.   On 11-Feb-2022, the patient received first dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On 11-Mar-2022, received second dose of mRNA-1273 (Spikevax) (unknown route) dosage was changed to 1 dosage form. On 11-Mar-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Dose given more than 12 hour post-puncture). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Dose given more than 12 hour post-puncture) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication information was provided.   It was reported that the vaccine was punctured on thursday morning 10-Mar-2022 at 9:24 AM. Date the vial was initially stored in the refrigerator was 10-Mar-2022 and the vial did not undergo any temperature excursions. Amount of time the vial was exposed to room temperature range (8° to 25°C= 46° to 77°F) was very minimal (only taken out to draw the doses).  No treatment medication were provided.
After receiving third Gardasil booster shot, was covered in itchy light-pink bumps all over my body for 2-3 days.
No adverse event. Patient was given Pfizer dose on 1/28/21 and received Moderna COVID vaccine on 2/18/21.
3-30-15 noted at bedtime. 4-1-15 11:45 call to office. Localized redness and swelling at inj site. Seen at 2 PM.
Patient developed a large rash on the arm and back after getting the second dose, causing her to go to the doctor for evaluation.
the patient developed swelling, inflammation, and pain at the injection site"; the patient developed swelling, inflammation, and pain at the injection site"; the patient developed swelling, inflammation, and pain at the injection site"; This spontaneous report was received from registered nurse via company representative refers to a 44 year old female patient. Information on patient's historical condition, concurrent condition and concomitant medication was not provided.  On 14-MAY-2019 (also reported as "6 days ago") the patient was vaccinated with hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast)(GARDASIL 9) (dose details, route of administration, lot, batch and expiration date were not reported) for prophylaxis.  In May 2019 (also reported as on an unspecified date, after the vaccination) the patient experienced swelling, inflammation and pain at the injection site (vaccination site swelling, vaccination site inflammation and vaccination site pain). At the time of report the outcome of vaccination site pain, vaccination site inflammation and vaccination site swelling was unknown. The causality of the events vaccination site pain, vaccination site inflammation and vaccination site swelling with respect to the suspect therapy hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast)(GARDASIL 9) was not provided. No product quality complaint involved.
I received my 5th dose of Pfizer Bivalent on 09/08/2022. My adverse event started on 09/15/2022. I had fatigue, cough, thick mucus, nasal drip, and chest congestions. I did a rapid test on the same day which was negative. On 09/16/2022 I still tested negative for COVID-19 on the rapid test. I did a PCR test on the 09/16/2022 evening and I got my result on the 09/17/2022. I already had a PAXLOVID prescription from my doctor a month before because my doctor was concerned with my health issues. On November I took AUGMENTIN because I had a thick mucus which wasn't going about. I developed Sinusitis. My salivary glands were swollen up. I also got Bronchitis. As of today 12/14/2022 I am still taking antibiotics. I haven't fully recovered yet. I still have the lingering thick mucus. My doctor is still trying to rule out the problem I have.
Freezing; Sweating; Achy; Headache; Loss of appetite; Fatigued; Light-headed; Itchy red hands; Itchy red hands; This is a spontaneous report from a contactable consumer, the patient. A 53-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 29Mar2021 at 11:00 (at the age of 53-years-old) as a single dose for COVID-19 immunisation. Medical history included fibromyalgia, ankylosing spondylitis, low thyroid and allergy to penicillin and sulfa. Concomitant medications included gabapentin (MANUFACTURER UNKNOWN), naproxen (MANUFACTURER UNKNOWN), etanercept (ENBREL), vitamins (MANUFACTURER UNKNOWN) and levothyroxine (MANUFACTURER UNKNOWN); all from unknown dates for unspecified indications. The patient previously received ampicillin (MANUFACTURER UNKNOWN), infliximab (INFLECTRA), erythromicin (MANUFACTURER UNKNOWN), amoxicillin (MANUFACTURER UNKNOWN) and tetracycline (MANUFACTURER UNKNOWN); all on unknown dates for unspecified indications and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 29Mar2021 at 20:00, the patient experienced freezing, sweating, achy, headache, loss of appetite, fatigued, light headed and itchy red hands. The patient stated that day 5 after injection was the worse so far. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events freezing, sweating, achy, headache, loss of appetite, fatigued, light headed and itchy red hands was recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
woke up with a weird sensation; could not move her left arm/cannot raise her arm at all; arm hurts/arm pain was horrible; cannot get comfortable; This spontaneous case was reported by a consumer and describes the occurrence of FEELING ABNORMAL (woke up with a weird sensation), MOBILITY DECREASED (could not move her left arm/cannot raise her arm at all), PAIN IN EXTREMITY (arm hurts/arm pain was horrible) and DISCOMFORT (cannot get comfortable) in a 64-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 044B21A and 028A21A) for COVID-19 vaccination.     No Medical History information was reported.   On 06-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 04-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 11-May-2021, the patient experienced FEELING ABNORMAL (woke up with a weird sensation), MOBILITY DECREASED (could not move her left arm/cannot raise her arm at all), PAIN IN EXTREMITY (arm hurts/arm pain was horrible) and DISCOMFORT (cannot get comfortable). The patient was treated with MENTHOL, METHYL SALICYLATE (BENGAY [MENTHOL;METHYL SALICYLATE]) for Pain in arm, at an unspecified dose and frequency and IBUPROFEN (MOTRIN [IBUPROFEN]) for Pain in arm, at a dose of 600 mg every six hours. At the time of the report, FEELING ABNORMAL (woke up with a weird sensation), MOBILITY DECREASED (could not move her left arm/cannot raise her arm at all), PAIN IN EXTREMITY (arm hurts/arm pain was horrible) and DISCOMFORT (cannot get comfortable) outcome was unknown.            No concomitant product was reported.  Patient used ice and heating pads on her arm as treatment.    This case was linked to US-MODERNATX, INC.-MOD-2021-128128 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2021-128128:created for dose 1
- Swelling - Tenderness - Soreness  - Cold sensation in left arm/hand - Pain
1449 Patient received first Pfizer pediatric dose.  1509 Father alerted RN, that daughter was feeling nauseated. RN saw that patient was pale and appeared dizzy. Pt attempted to walk from chair to gurney, and had moderate to large emesis x 2 ( food from lunch time). Patient sitting up on gurney, Vital signs: Temp Oral 98.2 F, BP Right Arm: 82/37 Pulse Rate 83. 1514 Called Pediatric MD stat 1516 Dr. Arrived at patients side. Patient states feeling better since throwing up, and currently tolerating sips of water and crackers. 1521 BP right Arm 98/70 , Pulse Rate 85. Patient appears pink and comfortable. 1522 Dr Evaluates Patient, awaiting Pediatric MD to arrive. 1530 Temp Oral 98.2 F 1538 Dr. arrives to patient, and patient evaluated. 1545 Patient okay to go home per Dr.'s evaluation, teaching for prior to 2nd dose given by Dr.
Patient recieved vaccination on 2/10/21. Was exposed to COVID and on 2/21/21 developed. tested positive on 2/25/21. Patient is currently  not hospitalized.
experienced cognitive disruption for approximately 4 hours.; Disruption included inability to read; difficulty with speech/context/numbers.; This is a spontaneous report from a contactable consumer (patient). A 14-years-old non-pregnant female patient received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Lot Number: EW0202 and Expiration Date: unknown), via an unknown route of administration, administered in left arm on 27Jun2021 at 13:00 (at the age of 14-years-old) as dose 2, single for covid-19 immunisation. The patient has no other medical history. The patient's concomitant medications were not reported. Patient has no known allergies. The patient previously took first dose of bnt162b2 (Lot number: EW0178) administered in left arm on 04Jun2021 at 12:00 PM (at the age of 14-years-old) as dose 1, single for covid-19 immunisation. Patient did not receive any other vaccine in four weeks. On 08Jul2021 at 10:00, 11 days after second dose, the patient experienced cognitive disruption for approximately 4 hours. Disruption included inability to read and difficulty with speech/context/numbers. The events resulted in emergency room/department or urgent care. Prior to vaccination, the patient was not diagnosed with covid-19 and not tested for covid-19 post vaccination. No treatment was received for the events. Outcome of events was recovered on an unknown date in Jul2021.